Axsome Therapeutics (NASDAQ:AXSM)報告季度每股虧損$(1.54)，未達到分析師普遍預期的$(1.03)，差距爲49.51%。相比去年同期每股虧損$(2.08)，這是一個25.96%的改善。公司報告季度銷售額爲$1.1877億，超出分析師普遍預期的$1.1764億，超出幅度爲0.95%。相比去年同期的$7153萬，銷售額增長了66.03%。

以上內容來自Benzinga Earnings專欄，原文如下：

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.54) per share which missed the analyst consensus estimate of $(1.03) by 49.51 percent. This is a 25.96 percent increase over losses of $(2.08) per share from the same period last year. The company reported quarterly sales of $118.77 million which beat the analyst consensus estimate of $117.64 million by 0.95 percent. This is a 66.03 percent increase over sales of $71.53 million the same period last year.